Evidence map›Paper›PMID 41851132›Full record

ArticleNPJ vaccines2026

A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humans.

Lark L Coffey, Katherine J Olstad, J Rachel Reader, Amir Ardeshir, Christopher M Weiss, Jennifer K Watanabe, Jodie L Usachenko, JoAnn Yee, Anil Singapuri, Zhong Min Ma and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Lark L CoffeyDepartment of Pathology, Microbiology, and Immunology, Weill School of Veterinary Medicine, University of California, Davis, Davis, CA, USA. lcoffey@ucdavis.edu.ORCID http://orcid.org/0000-0002-0718-5146
Katherine J OlstadDepartment of Pathology, Microbiology, and Immunology, Weill School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0003-3894-0981
J Rachel ReaderDepartment of Pathology, Microbiology, and Immunology, Weill School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.
Amir ArdeshirCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Christopher M WeissDepartment of Pathology, Microbiology, and Immunology, Weill School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.ORCID http://orcid.org/0000-0003-4704-9533
Jennifer K WatanabeCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Jodie L UsachenkoCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
JoAnn YeeCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Anil SingapuriDepartment of Pathology, Microbiology, and Immunology, Weill School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.
Zhong Min MaCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Alexis MackiewiczCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Rebecca SammakCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Jackson StuartDepartment of Pathology, Microbiology, and Immunology, Weill School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.
Ramya ImmareddyCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Ravi AnanthaEmergent Biosolutions, Gaithersburg, MD, USA.
Kelly L WarfieldEmergent Biosolutions, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0003-1866-5388
Darly ManayaniNovartis, San Diego, CA, USA.
Jeff AlexanderEmergent Biosolutions, Gaithersburg, MD, USA.
Jonathan SmithVLP Therapeutics, Gaithersburg, MD, USA.
Lo VangBavarian Nordic, San Diego, CA, USA.
Christopher M CirimotichBattelle Biomedical Research Center, West Jefferson, OH, USA.ORCID http://orcid.org/0000-0002-7636-0542
Cassandra O'ConnorBattelle Biomedical Research Center, West Jefferson, OH, USA.
Ben GuentherBavarian Nordic, San Diego, CA, USA.
Nhuxuan HoBavarian Nordic, San Diego, CA, USA.
Christopher S MorelloEmergent Biosolutions, Gaithersburg, MD, USA.
Jason MendyBavarian Nordic, San Diego, CA, USA.
Jason S RichardsonBavarian Nordic, Toronto, ON, Canada.
Koen K A Van RompayDepartment of Pathology, Microbiology, and Immunology, Weill School of Veterinary Medicine, University of California, Davis, Davis, CA, USA. kkvanrompay@ucdavis.edu.ORCID http://orcid.org/0000-0002-7375-1337

Funding

National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
NIH HHS P51 OD011104ORIP NIH HHS P51 OD011107
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) causes periodic outbreaks and is endemic in more than 110 countries. VIMKUNYA, a CHIKV virus-like particle (CHIKV VLP) vaccine, was recently approved by regulators in the United States, European Union, and United Kingdom. Efficacy of VIMKUNYA in endemic settings is difficult to evaluate due to outbreak unpredictability. We used cynomolgus macaques, which model human CHIKV viremia and disease, to assess CHIKV VLP vaccine efficacy. Doses as low as 1.25 μg of CHIKV VLP with aluminum hydroxide adjuvant and passively transferred IgG from vaccinated humans significantly reduced viremia, disease, and joint pathology. Animals that received IgG doses resulting in mean reciprocal 80% neutralization titers of 35, well below the predicted protective threshold of ≥100, exhibited improved clinical outcomes compared with CHIKV-infected control animals, suggesting clinical benefits may occur at lower antibody levels. These findings demonstrate immunogenicity and protective efficacy of CHIKV VLP and relevance of neutralizing antibodies in protection, reinforcing its use in humans to protect against chikungunya disease.

Identifiers

PMID41851132
PMCPMC13149838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.